Since no effective screening programme has yet been identified, prophylactic BSO should be advised to all high-risk women after they completed their family which will reduce the risk of ovarian cancer associated with BRCA1 or BRCA2 mutation by 70-96% [20-22]. The gene discussed is BRCA1; the disease is ovarian carcinoma.